Physician profile
Terrie Thomas
NPI 1740366376
$1,226.46
in general payments reported to CMS, 2019-2025
15 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $15.54 · 2021: $24.64 · 2022: $361 · 2023: $324 · 2024: $193 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $398.64 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $217.02 | 2020-2023 | Orilissa, Lo Loestrin Fe, Liletta |
| Gynesonics, INC. | $205.36 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Coloplast Corp | $62.31 | 2019 | |
| Dexcom, INC. | $61.40 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $59.69 | 2019-2024 | Evenity |
| Ethicon US, LLC | $47.09 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.66 | 2022-2025 | |
| Pacira Pharmaceuticals Incorporated | $30.25 | 2023 | Exparel, Iovera |
| Pfizer INC. | $24.32 | 2019-2022 | |
| Organon LLC | $19.74 | 2022 | |
| Merck Sharp & Dohme LLC | $18.43 | 2023 | Gardasil 9 |
| Sumitomo Pharma America, INC. | $16.06 | 2023 | Myfembree |
| Myovant Sciences INC. | $15.45 | 2022 | |
| Medtronic, INC. | $14.04 | 2023 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrie Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.